Replies to post #218463 on Biotech Values

[RockRat]

Re: GLPG1690 in IPF P3 plan: Speeding along, but risky. Small numbers in P2 - 23 patients! Much shorter treatment period, and it wasn't on top of SOC treatments.

Zoiks!

Regards, RockRat